Project Grant K99HL181309
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $129,600 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with an ultimate completion date of August 31, 2027. The award supports basic biomedical research investigating novel mechanisms of macrophage foam cell formation in atherosclerotic plaques. The research focuses on elucidating how...
- Federal Grant Award Summary Albany Medical College received a $586,474 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 15, 2026 through February 28, 2030. The project, titled "Targeting Lipolytic Sterol Signaling to Foster Favorable Foam Cell Modulation and Atheroprotection," supports basic research investigating mechanisms of atherosclerosis protection through lipid...
- Federal Project Grant Summary Weill Medical College of Cornell University received a $708,265 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2029. The award supports mechanistic research on fibroblast growth factor homologous factors (FHFs) and their regulation of cardiac ion channels. The research focuses on expanding understanding of how FHFs influence...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Weill Medical College of Cornell University a Project Grant of $109,076 (awarded March 3, 2026; completion date September 14, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to expand single-cell transcriptomics methodologies for studying noncoding RNAs in normal hematopoiesis. The primary deliverables include: (1) development of a computational pipeline to process and analyze...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1,151,500 to Columbia University's Health Sciences Division on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This seven-year project, extending through February 28, 2033, will investigate novel mechanisms of macrophage biology in atherosclerosis and its intersection with metabolic dysfunction-associated steatohepatitis (MASH). The research program will deliver...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $348,778 Project Grant to Weill Medical College of Cornell University on September 5, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports a K23 career development grant for Dr. Nupoor Narula focused on investigating graft stiffness as a substrate for adverse cardiovascular remodeling in patients with genetically triggered thoracic aortic aneurysms (GTAA). The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,400 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective September 1, 2025, through August 31, 2027, funds research investigating an athero-protective pathway mediated by macrophage tryptophan metabolism and aryl hydrocarbon receptor (AHR) activation. The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded New York University School of Medicine a $1.69 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) on June 5, 2026, with completion scheduled for February 29, 2028. This award funds research investigating immune mechanisms that impede atherosclerotic plaque regression in type 2 diabetes (T2D) patients. The research will examine gamma-delta (γδ) T cell expansion in arterial...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $791,503 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion targeted for June 30, 2029. The award funds research to identify novel roles and therapeutic potential of Protease Activated Receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome...
- Grant Award Summary Albany Medical College received a $1,634,428 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 5, 2026, with completion targeted for February 29, 2028. The grant funds mechanistic research investigating inflammation-resolution pathways within endothelial cells to address gaps in understanding why cholesterol-lowering treatments do not fully reduce cardiovascular...
Weill Medical College of Cornell University received a $129,600 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026 through May 31, 2028. The grant funds basic biomedical research to characterize the mechanisms underlying atherosclerosis development, specifically investigating a novel cellular process termed "digestive exophagy" by which macrophages break down aggregated low-density lipoprotein (AGLDL) particles in extracellular acidic compartments. The research deliverables focus on identifying and characterizing upstream and downstream molecular pathways that regulate this process, with particular emphasis on the lysosomal calcium channel TRPML1 (transient receptor potential mucolipin 1). The primary investigator will characterize reactive oxygen species as upstream modulators of TRPML1 function and examine synaptotagmin VII as a downstream effector controlling lysosome exocytosis. The study aims to determine whether modulating TRPML1 function can reduce atherosclerosis development, potentially informing the development of novel therapeutic interventions for cardiovascular disease. Work is being conducted at the institution's location in New York, New York.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $129.6k | 6/23/26 |